SGLT2 inhibitors represent one of the most transformative developments in diabetes medicine in the past decade. Originally approved as glucose-lowering
GLP-1 receptor agonists were originally developed to lower blood sugar. What researchers discovered in subsequent cardiovascular outcome trials was something